brand logo

Am Fam Physician. 2023;107(4):422-423

Author disclosure: No relevant financial relationships.

Clinical Question

Is metformin therapy more effective than therapeutic lifestyle changes in preventing progression to type 2 diabetes mellitus in patients with prediabetes?

Evidence-Based Answer

Metformin is more effective than standard lifestyle changes at preventing progression to type 2 diabetes. (Strength of Recommendation [SOR]: C, systematic review and meta-analysis of randomized controlled trials [RCTs] and RCT of disease-oriented outcomes.) [corrected] However, intensive lifestyle interventions are as effective as metformin. The effects of these interventions are enduring, with a continued benefit of intensive lifestyle interventions and metformin at 15 years of follow-up. (SOR: C, RCT of disease-oriented outcomes.) [correctred[ Patients with a body mass index (BMI) greater than 35 kg per m2, age younger than 60 years, higher fasting glucose or A1C, or a history of gestational diabetes benefit the most from using metformin to prevent the progression from prediabetes to type 2 diabetes. (SOR: C, RCT of disease-oriented outcomes.) [corrected]

Evidence Summary

A 2019 Cochrane review of 20 RCTs studied metformin for diabetes prevention for a follow-up period of one to three years.1 The metformin dosage varied drastically in these trials, from 38 mg per day to 3,000 mg per day. A total of 12 RCTs (n = 3,632) evaluated the incidence of type 2 diabetes in patients randomized to metformin therapy compared with those randomized to placebo or standard care (i.e., physician recommendations about healthy diet and exercise). These trials found that metformin was more effective (relative risk [RR] = 0.50; 95% CI, 0.38 to 0.65; P < .001). Seven RCTs (n = 2,960) compared the incidence of type 2 diabetes in patients randomized to metformin vs. intensive diet and lifestyle modification (defined differently among studies, but often including at least 30 minutes of exercise per day and structured visits with a dietitian). There was no significant difference between the two groups (RR = 0.80; 95% CI, 0.47 to 1.37; P = .42).

Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (https://www.cebm.net).

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to https://www.fpin.org or email: questions@fpin.org.

This series is coordinated by John E. Delzell Jr., MD, MSPH, associate medical editor.

A collection of FPIN’s Clinical Inquiries published in AFP is available at https://www.aafp.org/afp/fpin.

Continue Reading

More in AFP

More in PubMed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.